Tissue Repair: Hidden Gem in Biotech!, page-6

Thanks for the additional information.

I don't like a couple of things about Tony, another one is his pivot to running Mable and being mostly absent from TRP now days. Additionally, he doesn't come from a clinical or medical background nor any prior experience bringing a drug to market.

That said, the IP has been given no value by the market and the risk reward ratio on what is likely to be positive ph3 results is very attractive.

I hunt for the dead stocks. This is where the bags are made with very low capital.